Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term observational study of gene therapy for Parkinson's disease
jRCT2033220367Completed
- Sponsor
- Gene Therapy Research Institute
- Start
- Oct 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ezaladcigene resoparvovec in Parkinson's disease (PD), sponsored by Gene Therapy Research Institute. Primary endpoints: Long-term tolerability, Long-term safety and 1 more. Started Oct 2022; status: completed.
02
Drugs
ezaladcigene resoparvovec
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2033220367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033220367.